Lung Cancer | Tumor

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

June 6th 2021

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Gavreto ‘Very Well Tolerated’ in RET Fusion-Positive Non-Small Cell Lung Cancer

June 5th 2021

Findings demonstrated that Gavreto could clinically benefit those with RET fusion-positive non-small cell lung cancer, including those who are treatment naïve.

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

May 28th 2021

The agency approved Lumakras, the first targeted therapy for patients with non-small cell lung cancer and a KRAS G12C mutation, whose disease progressed after one systemic therapy.

FDA Approves Rybrevant for Certain Group of Patients with Non-Small Cell Lung Cancer

May 21st 2021

The decision from the Food and Drug Administration marks the first approval of a targeted treatment option for adults with non-small cell lung cancer whose tumors harbor a specific genetic mutation.

Treatment Considerations for TIL Therapy in NSCLC

May 18th 2021

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

Clinical Trials of TIL Therapy in NSCLC

May 18th 2021

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

The Potential Role of TIL Therapy in NSCLC

May 11th 2021

Adam J. Schoenfeld, MD, considers the benefits and limitations of tumor-infiltrating lymphocyte (TIL) therapy and discusses its potential impact on the treatment landscape in non–small cell lung cancer.

An Overview of TIL Therapy

May 11th 2021

An expert in the management of non–small cell lung cancer defines tumor-infiltrating lymphocyte (TIL) therapy by discussing its mechanism of action and reviewing its impact in other disease states, such as myeloma.

Cell Therapies for Patients With NSCLC

May 11th 2021

A key opinion leader in thoracic oncology discusses factors to consider regarding emerging cell therapy options in non–small cell lung cancer, such as CAR T, TCR, and TIL therapies.

Treatment Options in NSCLC After First-Line Therapy

May 11th 2021

Adam J. Schoenfeld, MD, provides key insights into treatment options for patients with non–small cell lung cancer whose tumors progress after first-line therapy.

Importance of Biomarker Testing in Non-Small Cell Lung Cancer

May 10th 2021

Bonnie Addario, a lung cancer survivor, explains the importance of comprehensive biomarker testing in patients with lung cancer to treat to target and coverage from insurance companies.

Most Patient Records Within A Large Cancer Registry-Based Real-World Data Source Have Missing Data

May 4th 2021

A significant number of patient records in large cancer registries are missing data, which can have an impact on real-world data studies.

The Different Roads of Lung Cancer

May 3rd 2021

We all handle things differently, look at things differently and understand differently, meaning that the journey of each patient with cancer is unique. But there are always similarities among the symptoms, risks and treatments.

Could T-Cell Therapy Be the Next Advancement in Lung Cancer Immunotherapy?

May 1st 2021

Over the past few years, lung cancer has changed significantly with improving outcomes, particularly attributable to immunotherapy, but how do we continue that trend?

Early Introduction to Supportive Care Greatly Benefits Older Patients With Lung Cancer

April 26th 2021

Because of their age, disease state and comorbid conditions, older patients need supportive care.

Quelling COVID-19 and Cancer Fears

April 25th 2021

As part of its “Speaking Out” video series, CURE® spoke with Katie Brown from LUNGevity about challenges that have arisen from the COVID-19 pandemic — including delays in screening — and resources to help patients through these trying times.

Offering Hope in the Lung Cancer Community

April 24th 2021

In partnership with CURE®, Bonnie J. Addario and the GO2 Foundation for Lung Cancer will release “The Living Room: A Lung Cancer Community of Courage,” a collection of stories from patients, caregivers and survivors taking a personal approach to cancer care.

Biomarker Testing Tool Empowers Patients With Lung Cancer

April 23rd 2021

The Cancer Support Community's Biomarker Testing Tool can help identify which targeted therapy should be used for treatment in patients with lung cancer.

No Small Challenge: Emerging Therapies in Small Cell Lung Cancer

April 21st 2021

In recent years, research in treating small cell lung cancer has broadened, bringing emerging therapies like immunotherapy to the forefront.

Cell-Based Therapies May ‘Level the Playing Field’ in Non-Small Cell Lung Cancer

April 20th 2021

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

Obesity May Be Associated with Increased Cancer Mortality in Most Cancers; Lower in Others

April 14th 2021

Recent study results demonstrated an possible association between a high BMI and risk of cancer and overall mortality, though patients with obesity and lung cancer, renal cell carcinoma and melanoma were found to have a lower risk of death than patients with the same cancers without obesity.

Webinar Recap: Know Your Lung Cancer: Accelerating Education and Access for Biomarker Testing

April 13th 2021

On Feb. 18, CURE hosted a webinar focused on educating patients on biomarker testing. Here, we highlight key takeaways from our panelists.

CURE®'s Educated Patient® Lung Cancer Summit At a Glance

April 10th 2021

Take a look back at CURE®’s Educated Patient® Lung Cancer Summit with this roundup of stories that highlight what was discussed at this half-day virtual event.

Looking Ahead in Lung Cancer Care

April 7th 2021

Beyond Lung Cancer Treatment

April 7th 2021

Small Cell Lung Cancer

April 7th 2021

Biomarker Testing in Lung Cancer

April 7th 2021

COVID-19 and Lung Cancer

April 7th 2021

CURE’s Top Stories: March 2021

April 1st 2021

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for March 2021.

Newly-Approved Lorbrena Shows Better Responses in Patients With Brain Metastases

March 31st 2021

The FDA recently approved an expanded indication for Lorbrena as a first-line treatment option for a subset of lung cancer that has spread to the brain. Compared to previously-approved options, experts say Lorbrena is more effective.